The U.S. Food and Drug Administration (FDA) announced on 2026-05-29 a significant revision to the label for products containing estradiol and norethindrone acetate. This update introduces a new boxed warning, the agency's strongest safety alert, highlighting serious risks including cardiovascular disorders, probable dementia, breast cancer, and endometrial cancer.
Background
Estradiol is a form of estrogen, a primary female sex hormone, and norethindrone acetate is a synthetic progestin. These hormonal components are found in various medications. The FDA's decision to add a boxed warning specifically addresses the safety profile of products containing this combination of hormones.
What this means
The implementation of a boxed warning on the label for estradiol and norethindrone acetate represents a critical safety communication from the FDA. This type of warning is reserved for situations where there is reasonable evidence of a serious hazard associated with the drug. For healthcare professionals, this means a heightened need to carefully assess patient risk factors for cardiovascular disorders, probable dementia, breast cancer, and endometrial cancer before prescribing or continuing treatment with these medications. Patient counseling should thoroughly cover these potential severe adverse effects. For patients, this update underscores the importance of discussing their full medical history and any concerns about these risks with their healthcare providers to ensure informed decision-making regarding their treatment.
Source
The U.S. Food and Drug Administration (FDA) issued this major label revision on 2026-05-29. The detailed prescribing information, including the complete boxed warning, is accessible via the DailyMed website, a comprehensive database of drug labels provided by the National Library of Medicine, at dailymed.nlm.nih.gov.